Form 4: Y-mAbs Therapeutics Director James Healy Receives Significant Equity Grants

Y-mAbs Therapeutics, Inc. Director James Healy was granted 25,080 restricted stock units and 33,450 employee stock options, signaling continued alignment with company performance.

Summary

• James Healy, a Director of Y-mAbs Therapeutics, Inc. (YMAB), was granted 25,080 restricted stock units (RSUs) and 33,450 employee stock options on June 30, 2025.
• The RSUs represent a contingent right to receive one share of common stock each and vest in full on the earlier of the first anniversary of the grant date (June 30, 2026) or the date immediately preceding the Issuer's annual meeting of stockholders in 2026, contingent on continued service.
• The stock options have an exercise price of $4.51 per share and vest in equal monthly installments until the first anniversary of the grant date (June 30, 2026), also subject to continued service, and are exercisable immediately upon vesting.
• Following these transactions, James Healy directly beneficially owns 56,683 shares of common stock and 33,450 employee stock options.
• Additionally, James Healy indirectly beneficially owns 2,194,278 shares of common stock through Sofinnova Venture Partners X, L.P., where he is a managing member of the general partner, though he disclaims beneficial ownership except to the extent of his proportionate pecuniary interest.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it indicates continued commitment and incentivization of a key director through equity grants, which aligns interests with long-term company performance. It's a routine compensation event, not a major catalyst.

Positives

• The grants of restricted stock units and stock options align the director's interests with long-term shareholder value through performance-based incentives.
• The vesting schedules for both RSUs and stock options encourage continued service and commitment from the director.

Negatives

• No immediate negative financial implications are apparent from this Form 4 filing, as it primarily details equity grants rather than sales or adverse events.

Risks

• The value of the granted RSUs and stock options is subject to the future market performance of Y-mAbs Therapeutics' common stock.
• Vesting of both the RSUs and stock options is contingent upon the reporting person's continued service to the Issuer, meaning forfeiture could occur if service ceases before vesting.

Future Outlook

The equity grants are tied to future service and performance, indicating an expectation of continued engagement and contribution from the director to the company's long-term success.

Industry Context

Equity grants to directors and executives are a standard practice in the biotechnology and pharmaceutical industry, including companies like Y-mAbs Therapeutics, to incentivize long-term commitment and align leadership interests with shareholder value. This filing reflects a routine compensation event within the sector.

Comparison to Industry Standards

• The granting of RSUs and stock options to directors is a common compensation strategy across the biotechnology and pharmaceutical industry, comparable to practices at companies such as BioNTech, Moderna, or Regeneron Pharmaceuticals, which frequently use equity-based incentives to attract and retain top talent.
• The vesting schedules, tied to continued service over one year, are typical for such grants, aiming to ensure sustained commitment from key personnel.
• The exercise price of $4.51 for the stock options would be evaluated against the company's stock price on the grant date to assess the immediate 'in-the-money' or 'out-of-the-money' status, a standard metric in executive compensation analysis.

Related Party Transactions

• James Healy's indirect beneficial ownership of 2,194,278 shares through Sofinnova Venture Partners X, L.P., where he is a managing member of the general partner, represents a related party interest. He disclaims beneficial ownership except for his proportionate pecuniary interest.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the company's long-term stock performance, potentially benefiting shareholders if the company's value increases.
• Employees: No direct impact on general employees is indicated by this filing, though it reflects standard executive compensation practices.
• Management: The grants incentivize continued service and strategic contribution from a key director.

Next Steps

• Monitoring the vesting of the restricted stock units and stock options on their respective schedules, contingent on the director's continued service.
• Observing any future Form 4 filings by James Healy for potential sales or additional acquisitions of Y-mAbs Therapeutics securities.

Key Dates

Keywords

Y-mAbs Therapeutics, YMAB, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Incentive Plan, Director Compensation, Beneficial Ownership